To evaluate the long-term safety and efficacy of low vault posterior chamber collagen copolymer phakic intraocular lens (pIOL) implantation to correct myopia.

Of the total 311 patients underwent in this study, 12 eyes out of 10 cases with low vault ( ≤150µ) were enrolled in this study. Uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA), pIOL vault, endothelial cell loss, and adverse events were evaluated for 3 years after implantation of the Visian Implantable Collamer Lens pIOL for moderate to high myopia.

The mean spherical equivalent (12 eyes) decreased from -8.19 ± 2.69 preoperatively to -0.85±0.68 diopters, 3 years postoperatively.In term of visual outcomes, the mean UDVA ( LogMAR ) improved significantly from 1.13 ±027 to 0.31 ± 0.34 and mean CDVA improved (from 0.08 ± 0.09 to 0.06 ± 0.08) (P<0.05). The mean safety and efficacy indices were 1.039 and 0.706, respectively. No eye lost more than 2 lines of visual acuity; 82% Achieved 0.80 or better CDVA. The total endothelial cell loss (consider cumulatively at consecutive intervals through 3 years) was 9.7 %. No vision-threatening complications occurred.

: Implantation of the low vault collagen copolymer pIOL for moderate to high myopia was safe and effective and provided long-term predictable, stable refractive results.